Royalty Pharma plc

- Royalty Pharma currently has $9.2 billion of investment-grade debt with a weighted average duration of around 12 years. - They have a $1.8 billion revolver facility, which is currently undrawn. - Total financial flexibility is approximately $4 billion, combining cash on hand, cash generated by the business, and access to debt markets. - The leverage ratio stands at 2.9x total debt to adjusted EBITDA, indicating low leverage and significant financial capacity. - The balance sheet is described as strong, and no immediate constraints on capital deployment exist. - There is no specific mention of new fundraising through debt or equity planned imminently. - The company is prepared to invest more capital if deal flow increases, leveraging its strong balance sheet and access to capital markets.

- Royalty Pharma has significant capital flexibility, with the capability to invest around $30 billion. - Annual guided investment is ~$2 billion to $2.5 billion. - An additional $10 billion capacity exists to increase investments if attractive opportunities arise. - Potential to deploy up to $20 billion over the next 5 years in royalty acquisitions. - New strategic focuses include expansion into China, viewed as a key driver of capital deployment and growth. - Increasing activity in co-funding R&D with large global biopharma companies, which was previously underrepresented in capital deployment guidance. - Recent deals with J&J and Teva highlight $1 billion of announced value in R&D co-funding. - Leveraging data and AI to enhance investment decisions and partnership value. - Financial capacity supported by strong balance sheet and $4 billion in accessible capital (cash, debt markets, revolver). Overall, Royalty Pharma is poised for flexible and strategic capital deployment across existing royalties, R&D co-funding, and expansion into new markets like China.

- Royalty Pharma expects strong low-volatility top and bottom line growth through 2030 and beyond, driven by diversified and expanding biopharma royalty market. - Full-year 2026 portfolio receipts guidance was raised to $3.325 billion - $3.45 billion, reflecting 4%-8% growth in royalty receipts despite headwinds from loss of exclusivity and biosimilar launches. - Growth fueled by strong product momentum (e.g., Tremfya, Voranigo, Evrysdi) and pipeline developments with multiple pivotal readouts anticipated in 2026-2027. - Expansion into R&D co-funding with global biopharma and in China is expected to accelerate capital deployment and future revenue streams. - Pipeline includes promising therapies with blockbuster potential, e.g., cardiovascular and multiple sclerosis drugs, expected to unlock substantial value. - Capital deployment capacity of around $30 billion with ability to invest up to $20 billion over the next 5 years in royalty acquisitions, supporting growth. - Expect continued double-digit average growth since IPO, underpinned by disciplined investment strategy and evolving funding modalities.

- Royalty Pharma raised its full-year 2026 financial guidance, expecting portfolio receipts between $3.325 billion and $3.45 billion, reflecting 4% to 8% growth in royalty receipts. - The company anticipates strong low-volatility top and bottom line growth through 2030 and beyond. - Return on invested capital stood at 14.1%, and return on invested equity at 19.7% (last 12 months ending Q1 2026), indicating attractive returns. - Continued deployment of capital into attractive royalty deals ($528 million in Q1 2026) supports growth. - Growth is fueled by multiple upcoming pivotal readouts and product launches in 2026-2027. - Increasing emphasis on R&D co-funding with global biopharma and expansion into China represent significant growth opportunities. - Dividend increased by 7%, and share repurchases continue, signaling confidence in earnings growth. - Overall, the firm sees a clear path for compounding earnings and shareholder value creation.

- Royalty Pharma has significant capital deployment capacity, with the ability to invest around $30 billion overall. - Of this, approximately $12 billion is guided at $2 billion to $2.5 billion per year. - Additional $10 billion capacity exists for increasing investments if opportunities arise, potentially deploying $20 billion over the next five years in royalty acquisitions. - Recent deals with big pharma (e.g., J&J, Teva) totaling $1 billion announced in Q1 indicate growing co-funding opportunities. - The China market is emerging as a new driver for capital deployment, with management actively building a platform and expecting significant deal flow. - Financial flexibility includes $4 billion of capacity and low leverage (2.9x debt to EBITDA), enabling readiness for increased deal flow. - The arbitration dispute with Vertex is expected to be resolved by mid-2027, which may impact orderbook timing.